Dispose of your used needles in a sharps bin
If you see no changes after 8-12 weeks at a therapeutic dose, discuss with your provider
Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
Retatrutide, a GIP, GLP-1, and Glucagon Receptor Agonist, for People with Type 2 Diabetes: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial. The New England Journal of Medicine
Why Lenreey SMGT-GLP-1 Patch Raises Major Concerns Lenreey markets itself as a high-tech microneedle patch that mimics the effects of GLP-1 agonists like Semaglutide
07.01.24 Judge issues filing to reduce admin delays Judge Karen Marston issued a Direct Filing Order allowing individuals alleging harm from Wegovy and other semaglutide drugs to join the MDL by filing directly in the MDL with the U.S